Abstract：Objective: To investigate the expression level of long noncoding RNA（lncRNA） plasmacytoma variant translocation 1 gene(PVT1) in plasma of patients with colorectal cancer and its clinical significance. Methods: The plasma samples were collected from 90 patients with colorectal cancer, 30 patients with colorectal adenoma, 42 healthy controls and 29 matched colorectal cancer patients for 2-3 weeks after operation. The expression of lncRNA PVT1 was detected by quantitative real time PCR(qRTPCR)in all samples and 29 patients with colorectal cancer were compared before and after operation. The correlation between plasma PVT1 expression and clinicopathological parameters of colorectal cancer was further analyzed, and receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficiency of plasma PVT1 for colorectal cancer. Results: The expression levels of plasma PVT1 in the colorectal adenoma group, the colorectal cancer group and the relative early TNM Ⅰ/Ⅱ colorectal cancer group were all significantly higher than those in the health group (all P<0.05) and decreased significantly after operation (P<0.01). And they were not correlated with the age, sex and tumor location, size, differentiation degree, TNM stage (all P>0.05). All diagnostic efficacy of the plasma PVT1 in the diagnosis of colorectal cancer were higher than conventional tumor marker carcinoembryonic antigen(CEA). The diagnostic value of combined detection of PVT1 and CEA for both colorectal cancer and TNM Ⅰ/Ⅱ colorectal cancer were higher than that of PVT1 and CEA alone. Conclusion: The upregulated plasma lncRNA PVT1 expression in patients with colorectal cancer and precancerous lesions could be served as a potential circulating marker for the clinical diagnosis and postoperative monitoring of colorectal cancer.
［1］Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012\[J\]. CA Cancer J Clin, 2015, 65(2):87-108.［2］Pawa N, Arulampalam T, Norton JD. Screening for colorectal cancer: established and emerging modalities\[J\]. Nat Rev Gastroenterol Hepatol, 2011, 8(12):711-722.［3］Tinzl M, Marberger M, Horvath S, et al. DD3PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer\[J\]. Eur Urol, 2004, 46（2）:182-187.［4］Dong L, Qi P, Xu MD, et al. Circulating CUDR, LSINCT5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls\[J\]. Int J Cancer, 2015, 137(5):1128-1135.［5］Takahashi Y, Sawada G, Kurashige J, et al. Amplification of PVT1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers\[J\]. Br J Cancer, 2014, 110(1):164-171.［6］Tong YS, Wang XW, Zhou XL, et al. Identification of the long noncoding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma\[J\]. Mol Cancer, 2015, 14:3.［7］Livak KJ, Schmittgen TD. Analysis of relative gene expression data using realtime quantitative PCR and the 2-△△ CT method\[J\]. Methods, 2001, 25(4): 402-408.［8］Ling H, Spizzo R, Atlasi Y, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer\[J\]. Genome Res, 2013, 23（9）: 1446-1461.［9］Qi P, Xu MD, Ni SJ, et al. Downregulation of ncRAN, a long noncoding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients\[J\]. Mol Carcinog, 2015, 54（9）: 742-750.［10］Zhai H, Fesler A, Schee K, et al. Clinical significance of long intergenic noncoding RNAp21 in colorectal cancer\[J\]. Clin Colorectal Cancer, 2013, 12（4）: 261-266.［11］Xie H, Ma H, Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma\[J\]. Biomed Res Int, 2013, 2013:136106.［12］Zhao W, Song M, Zhang J, et al. Combined identification of long noncoding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma\[J\]. Int J Clin Exp Pathol, 2015, 8（11）:14131-14140.［13］Gao J, Cao R, Mu H. Long noncoding RNA UCA1 may be a novel diagnostic and predictive biomarker in plasma for early gastric cancer\[J\]. Int J Clin Exp Pathol, 2015, 8(10):12936-12942.［14］Yu J, Han J, Zhang J, et al. The long noncoding RNAs PVT1 and uc002mbe.2 in sera provide a new supplementary method for hepatocellular carcinoma diagnosis\[J\]. Medicine (Baltimore), 2016, 95(31):e4436.［15］Yang JP, Yang XJ, Xiao L, et al. Long noncoding RNA PVT1 as a novel serum biomarker for detection of cervical cancer\[J\]. Eur Rev Med Pharmacol Sci, 2016, 20(19):3980-3986.［16］Chen X, Gao G, Liu S, et al. Long noncoding RNA PVT1 as a novel diagnostic biomarker and therapeutic target for melanoma\[J\]. Biomed Res Int, 2017, 2017:7038579.［17］Li N, Feng XB, Tan Q, et al. Identification of circulating long noncoding RNA Linc00152 as a novel biomarker for diagnosis and monitoring of nonsmallcell lung cancer\[J\]. Dis Markers, 2017, 2017:7439698.［18］Ren S, Wang F, Shen J, et al. Long noncoding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasmabased biomarker for diagnosing prostate cancer\[J\]. Eur J Cancer, 2013, 49（13）:2949-2959.［19］Shao Y, Ye M, Jiang X, et al. Gastric juice long noncoding RNA used as a tumor marker for screening gastric cancer\[J\]. Cancer, 2014, 120(21):3320-3328.［20］Kamel MM, Matboli M, Sallam M, et al. Investigation of long noncoding RNAs expression profile as potential serum biomarkers in patients with hepatocellular carcinoma\[J\]. Transl Res, 2016, 168:134-145.［21］周旭军,关秀军,包艳春. 联合检测血清癌胚抗原、CA125、CA199和CA724对大肠癌临床价值的探讨\[J\].现代肿瘤医学, 2014, 22(12):2938-2940.［22］Fu Z, Qian F, Yang X, et al. Circulating miR222 in plasma and its potential diagnostic and prognostic value in gastric cancer\[J\]. Med Oncol, 2014, 31(9):164.［23］Jin C, Shi W, Wang F, et al. Long noncoding RNA HULC as a novel serum biomarker for diagnosis and prognosis prediction of gastric cancer\[J\]. Oncotarget, 2016, 7(32):51763-51772.
2018, Vol. 28 
